Investment trends and themes in Health, Med and Tech
Glen Cross - Director, Captix Biomedical
Joseph Mocanu - Verge HealthTech Fund
Mr Tong Hsien-Hui - Head of Venture Investing, SGInnovate
Leslie Chong - Imugene MD CEO
Dr Damian Slizys - Kobold Ventures
Venture Capital / Life Sciences / Pharmaceuticals
Kobold Ventures is seeking expressions of interest for a fund to invest in early stage Australian life science companies, with a particular focus on therapeutic products (for example, new pharmaceuticals for treatment for diseases such as cancer).
Established in 2010, Livac Pty Ltd (Livac), a wholly owned subsidiary of LiVac Holding Co. Pty Ltd (Company), is a commercial-stage surgical devices company focused on the development and commercialisation of novel surgical devices to improve surgery and patient outcomes. Our first device, the LiVac® Retractor is in market, and suitable for use in upper abdominal surgery where the liver is required to be retracted to enable access to the underlying surgical field.
Healthcare / Biotechnology / Medical Devices / Advanced Materials
Captixbio is a pioneering Australian company developing innovative medical technologies to optimise the therapeutic impact of cell therapies. Founded in 2018 by Orthopaedic Surgeon, Dr Michael McAuliffe, in response to his own daughter’s diagnosis with Type 1 diabetes, Captixbio’s IMITATM device is an immuno-protective cell encapsulation and delivery technology intended to transform the current cell therapy paradigm for treatment of Type 1 diabetes (T1D).
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. Our unique platform technology seeks to harness and promote the body’s immune system against cancerous tumours. Our product pipeline includes oncolytic viruses and B-cell immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies.
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad-spectrum activity designed to address the urgent global health problem of antibiotic-resistant superbugs.
Healthcare / Biotechnology / Life Sciences / Pharmaceuticals
AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing targeted cancer therapies. AUM focuses on early stage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.